Business
New to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday, January 29, 2024, at 10:30 PM PT
New to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday, January 29, 2024, at 10:30 PM PT.
About this update from Sustainable Green Team, Ltd.
[{"type":"text","content":"\n NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) --  FMW Media's New to The Street, a national TV show, announces episode 551, airing on the FOX Business Network on Monday, January 29, 2024, at 10:30 PM PT. New to The Street's 551st episode line-up features the following Five (5) Corporate interviews: 1). Biopharmaceutical -Acurx Pharmaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO. 2). Financial Marketplace Strategies – Blue Castle Ventures LTD's ($BCVD) interviews with David Rojas, CEO/Founder. 3). Decentralized Supercomputing – Dynex's (CRYPTO: DNX) ($DNX) interview with Clifford Mapp, an Independent Technology Expert and Blockchain Pioneer. 4). Sustainable Solutions - The Sustainable Green Team, Ltd.'s (OTCQX: SGTM) ($SGTM) interview with Tony Raynor, CEO and Founder. 5). \"Sekur Privacy & Sekur Security – Weekly Hack” segment with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®). Episode 551 New to The Street's TV Host Jane King from the Nasdaq MarketSite Studio talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP). As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections. David updates viewers on the Company's FDA  Phase 2 clinical trial on the Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI). Based on positive data from Phase 2a and Phase 2b, management is now going forward with the FDA Phase 3. The Company compared its top-line data with the currently used standard-of-care drugs in the marketplace, and Ibezapolstat has impressive positive results. Phases 2a and 2b confirmed that the drug had success in 25 out of 26 patients, approximately 94% success with no reinfections. In treated patients, the microbiome bacteria found in the digestive tract shows the bacteria maintaining and restoring itself within those patients after a 10-day treatment. At a recent microbiome conference presentation in Texas, the Company compared logarithmic results from a competitor drug (vancomycin) to that of its Ibezapolstat drug, showing the differences in the effects on gut microbiome bacteria. Competitor drugs have been used for...